Another monoclonal antibody, Ramucirumab, targeting VEGFR2, is currently being used for advanced gastric cancer, non-small cell lung cancer, metastatic colorectal cancer, and hepatocellular carcinoma (HCC) [233,239,240,241]. The gene discussed is KDR; the disease is hepatocellular carcinoma.